Duloxetine (Generic Cymbalta) - Product information and Uses

Duloxetine is a serotonin-norepinephrine reuptake inhibitor which is effective for major depressive disorder and has been shown to be as effective as venlafaxine for generalized anxiety disorder (GAD). Duloxetine alleviates pain associated with diabetic neuropathy and fibromyalgia.
The main uses of duloxetine are in major depressive disorder, general anxiety disorder, stress urinary incontinence, painful peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain associated with osteoarthritis and chronic lower back pain.

Duloxetine - Availability And Packaging

Duloxetine is available as Generic Cymbalta Capsules which is packaged in 20 mg, 30 mg and 40 mg capsules. Generic Cymbalta is also available as Ariclaim, Xeristar, Yentreve, Duzela

Side Effects of Duloxetine (Generic Cymbalta)

The main side effects of Generic Cymbalta are Nausea, somnolence, insomnia, and dizziness.
In a trial for mild major depressive disorder (MDD), the most commonly reported treatment-emergent adverse events among duloxetine-treated patients were nausea (34.7%), dry mouth (22.7%), headache (20.0%) and dizziness (18.7%), and except for headache, these were reported significantly more often than in the placebo group.Duloxetine and SSRIs have been shown to cause sexual side effects in some patients, both males and females.
Adverse effects temporally correlated to Cymbalta therapy that were reported postmarketing include rash, reported rarely, and the following adverse events, reported very rarely: alanine aminotransferase increased, alkaline phosphatase increased, anaphylactic reaction, angioneurotic edema, aspartate aminotransferase increased, bilirubin increased, glaucoma, hepatitis, hyponatremia, jaundice, orthostatic hypotension (especially at the initiation of treatment), Stevens-Johnson syndrome, syncope (especially at initiation of treatment), and urticaria.

Duloxetine (Generic Cymbalta) - Dosage

Cymbalta should generally be administered once a day without or without meals. The starting adult dose for Major Depressive Disorder (MDD) is 40 mg/day to 60 mg/day.

Duloxetine (Generic Cymbalta) - Contraindications

Below are listed the contraindications of Generic Cymbalta:

  • Hypersensitivity - duloxetine is contraindicated in patients with a known hypersensitivity to duloxetine or any of the inactive ingredients.
  • MAOIs - concomitant use in patients taking MAOIs is contraindicated.
  • Uncontrolled narrow-angle glaucoma - in clinical trials, Cymbalta use was associated with an increased risk of mydriasis (dilation of the pupil); therefore, its use should be avoided in patients with uncontrolled narrow-angle glaucoma, in which mydriasis can cause sudden worsening.
  • CNS acting drugs - given the primary central nervous system (CNS) effects of duloxetine, it should be used with caution when it is taken in combination with or substituted for other centrally acting drugs, including those with a similar mechanism of action.
  • Cymbalta and thioridazine should not be co-administered.


Withdrawal Symptoms of Duloxetine (Generic Cymbalta)

During marketing of Cymbalta as well as other SSRIs and SNRIs, there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomia, hypomania, tinnitus, and seizures. The withdrawal syndrome from duloxetine resembles the SSRI discontinuation syndrome.
When discontinuing treatment with duloxetine (Generic Cymbalta), a gradual reduction in the dose is recommended, rather than abrupt cessation, whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, your doctor may continue decreasing the dose but at a more gradual rate.
In MDD placebo-controlled clinical trials of up to nine weeks' duration, systematically evaluating discontinuation symptoms in patients taking duloxetine following abrupt discontinuation found the following symptoms occurring at a rate greater than or equal to 2% and at a significantly higher rate in duloxetine-treated patients compared to those discontinuing from placebo: dizziness, nausea, headache, paresthesia, vomiting, irritability, and nightmare.

Additional Information

Additional Info: Prescribing Information

Considerable portions of the text here is from http://en.wikipedia.org/wiki/Duloxetine and is reproduced here under the Creative Commons Attribution-ShareAlike License